Migraine is a debilitating disease with high clinical and social impacts. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology, and specific medications targeting this have become available. The gepants are small molecules that block the CGRP docking station or CGRP receptor, and unlike the large injectable monoclonal antibodies, the gepants are available in oral and nasal formulations. Currently, there are four gepants either approved or in final studies before approval: ubrogepant, rimegepant, atogepant, and zavegepant. During recent neurology conferences, migraine experts have shared noteworthy developments regarding the use of gepants, including clinical trial results, potential new indications, and recent FDA submissions.

Explore the most recent updates on the use of gepants from the leading authorities Richard Lipton, MD, Albert Einstein College of Medicine; Stewart Tepper, MD, Dartmouth-Hitchcock Medical Center; and Jessica Ailani, MD, MedStar Georgetown University Hospital.